Log In
Print this Print this

MoNuDin (OXB-103)

  Manage Alerts
Collapse Summary General Information
Company Oxford BioMedica plc
DescriptionNeuroprotective gene therapy, VEGF delivered using OXB's LentiVector
Molecular Target
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector: Lentivirus
Latest Stage of DevelopmentPreclinical
Standard IndicationNerve damage
Indication DetailsTreat motor neuron diseases
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today